Vincerx Pharma, Inc.
Vincerx Pharma aspires to conquer cancer by addressing unmet medical needs with paradigm-shifting therapeutics. The company is engaged in developing a pipeline of innovative cancer treatments, including targeted therapies and immunotherapies, with a focus on solid tumors and hematologic malignancies. Their mission is to deliver first-in-class and best-in-class therapeutics through rigorous discovery and clinical development.
Industries
Nr. of Employees
small (1-50)
Products
VIP236 (small-molecule drug conjugate targeting αvβ3)
Investigational small-molecule drug conjugate using an optimized camptothecin payload designed for targeted delivery to tumors expressing αvβ3; under Phase 1 dose-escalation study for advanced solid tumors.
VIP943 (anti-CD123 ADC with KSP inhibitor payload)
Investigational antibody-drug conjugate targeting CD123 that incorporates a kinesin spindle protein inhibitor payload; indicated for leukemias and myelodysplastic syndromes in preclinical/early clinical development.
VIP924 (anti-CXCR5 ADC with KSP inhibitor payload)
Investigational antibody-drug conjugate targeting CXCR5 using a KSP inhibitor payload; developed for B‑cell malignancies and in preclinical/early clinical stages.
Anti-CD33 ADC with KSP inhibitor payload (investigational)
Investigational ADC targeting CD33 with a KSP inhibitor payload intended for leukemias and myelodysplastic syndromes; listed in the early-stage oncology pipeline.
Enitociclib (CDK9 inhibitor, also referenced as VIP152)
Investigational CDK9 (P-TEFb) inhibitor advanced into a Phase 1 dose-escalation study in combination with other agents; clinical trial conducted in partnership with an external NIH institute.
Undisclosed KSPi ADC programs (two solid tumor targets and one undisclosed hematologic target)
Multiple additional early-stage ADC programs employing KSP inhibitor payloads against undisclosed solid tumor and hematologic targets, listed as part of the oncology pipeline.
VIP236 (small-molecule drug conjugate targeting αvβ3)
Investigational small-molecule drug conjugate using an optimized camptothecin payload designed for targeted delivery to tumors expressing αvβ3; under Phase 1 dose-escalation study for advanced solid tumors.
VIP943 (anti-CD123 ADC with KSP inhibitor payload)
Investigational antibody-drug conjugate targeting CD123 that incorporates a kinesin spindle protein inhibitor payload; indicated for leukemias and myelodysplastic syndromes in preclinical/early clinical development.
VIP924 (anti-CXCR5 ADC with KSP inhibitor payload)
Investigational antibody-drug conjugate targeting CXCR5 using a KSP inhibitor payload; developed for B‑cell malignancies and in preclinical/early clinical stages.
Anti-CD33 ADC with KSP inhibitor payload (investigational)
Investigational ADC targeting CD33 with a KSP inhibitor payload intended for leukemias and myelodysplastic syndromes; listed in the early-stage oncology pipeline.
Enitociclib (CDK9 inhibitor, also referenced as VIP152)
Investigational CDK9 (P-TEFb) inhibitor advanced into a Phase 1 dose-escalation study in combination with other agents; clinical trial conducted in partnership with an external NIH institute.
Undisclosed KSPi ADC programs (two solid tumor targets and one undisclosed hematologic target)
Multiple additional early-stage ADC programs employing KSP inhibitor payloads against undisclosed solid tumor and hematologic targets, listed as part of the oncology pipeline.
Services
Collaborative partnerships to co-conduct early-phase oncology clinical trials with external institutions and investigators.
Collaborative partnerships to co-conduct early-phase oncology clinical trials with external institutions and investigators.
Expertise Areas
- Antibody-drug conjugate development
- Small-molecule drug conjugates
- Oncology drug discovery
- Early-phase clinical trial management (Phase 1 dose-escalation)
Key Technologies
- Antibody-drug conjugates (ADC)
- Small-molecule drug conjugates (SMDC)
- Kinesin spindle protein (KSP) inhibitor payloads
- Optimized camptothecin payloads
News & Updates
Vincerx will present three posters at the AACR Annual Meeting 2024.
Vincerx will present three posters at the AACR Annual Meeting 2024.